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ABSTRACT
Tumor microenvironments are characterized by decreased oxygen and nutrition 
due to the rapid and progressive nature of tumors and also stresses induced by several 
anti-tumor therapies. These intense cell stressors trigger a protective cell survival 
mechanism heralded by the unfolded protein response (UPR). The UPR is induced by 
an accumulation of unfolded proteins in the endoplasmic reticulum (ER) following cell 
starvation. Although the ER stress response is implicated in cytoprotection, its precise 
role during anti-angiogenic therapy remains unclear. One of the major proteins involved 
in ER stress is glucose-regulated protein 78 (GRP78), which binds to unfolded proteins 
and dissociates from membrane-bound ER stress sensors. To determine the role of 
ER stress responses during anti-angiogenic therapy and the potential role of GRP78 
in combined therapy in renal cell carcinoma (RCC), we used GRP78 overexpressing 
or knockdown RCC cells under hypoxic or hypoglycemic conditions in vitro and in 
animal models treated with sunitinib. Here, we report that GRP78 plays a crucial 
role in protecting RCC cells from hypoxic and hypoglycemic stress induced by anti-
angiogenic therapy. Knockdown of GRP78 using siRNA inhibited cancer cell survival and 
induced apoptosis in RCC cells in vitro and also resulted in ER stress-induced apoptosis 
and hypoxic/hypoglycemic stress-induced apoptosis by inactivating the PERK/eIF-2α 
pathway. Finally, GRP78 knockdown showed potent suppression of tumor growth and 
enhanced the antitumor effect of sunitinib in RCC xenografts. Our findings suggest that 
GRP78 may serve as a novel therapeutic target in combination with anti-angiogenic 
therapy for the management of RCC.
INTRODUCTION
Recently developed targeted therapies have 
shown promising results in the treatment of advanced 
malignancies. In particular, anti-angiogenic therapies 
that target vascular endothelial growth factor (VEGF) 
signaling have demonstrated remarkable clinical benefits 
in patients with advanced renal cell carcinoma (RCC) 
[1–3]. Targeting tumor angiogenesis induces severe 
tumor starvation, at which point, oxygen and nutrition 
deprivation successfully inhibits tumor growth and 
leads to disease stabilization. Sunitinib, one of the most 
efficacious multi-tyrosine kinase inhibitors targeting 
VEGF, significantly prolongs progression-free survival in 
patients with advanced RCC and is a first-line therapy for 
metastatic RCC [1]. However, anti-angiogenic therapy is 
generally not cytotoxic but rather cytostatic; thus, tumors 
shrink and regress, but many tumor cells survive anti-
angiogenic treatment and resume growth following an 
interval of stability. Once the tumor acquires resistance 
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to the anti-angiogenic agent, the tumor rapidly progresses 
and the prognosis is very poor, even with second- and 
third-line treatment options.
Tumors are often exposed to harsh 
microenvironments. Due to their rapid and progressive 
nature, tumors are surrounded by limited resources, 
such as oxygen and nutrients. Moreover, many cancer 
therapeutics deprive tumors of essential resources 
for cancer cell survival. These intrinsic and extrinsic 
environmental stressors generally induce the accumulation 
of unfolded proteins in the endoplasmic reticulum (ER) of 
cancer cells [4–5]. There, they elicit the unfolded protein 
response (UPR), a general cellular defense mechanism that 
dampens non-essential global protein synthesis to protect 
cells from stress. Many ER-resident proteins display 
altered expression patterns in cancer.
One of the most abundant ER-resident proteins is 
the ER chaperone glucose-regulated protein 78 (GRP78), 
also known as immunoglobulin heavy-chain-binding 
protein (BiP) [6]. A major UPR response is the induction 
of GRP78/BiP, which is highly expressed in a variety of 
tumors, including prostate cancer, melanoma, and head 
and neck cancer [7], and confers drug resistance in both 
proliferating and dormant cancer cells. GRP78 binds to 
unfolded proteins and dissociates from the membrane-
bound ER stress sensors; dissociation of GRP78 allows the 
subsequent activation of stress sensors, which suppresses 
global mRNA translation to protect cells from excessive 
amounts of unfolded proteins [8]. This adaptive response 
activated by the accumulation of unfolded proteins in the 
ER is mediated by at least three ER proximal sensors: 
PKR-related ER kinase (PERK), inositol requiring 
enzyme-1 (IRE1) and activating transcription factor 
(ATF) 6 [9]. PERK is a serine/threonine kinase that 
phosphorylates eukaryotic translation initiation factor 2A 
(eIF2a), a translation initiation factor that functions in 
the early steps of protein synthesis by forming a ternary 
complex with GTP and initiator tRNA during stress and 
consequently attenuates global protein translation [9]. 
A recent study revealed that GRP78 is highly expressed 
in RCC cells and suggested a significant relationship 
between GRP78 expression and clinicopathological 
features of RCC, including tumor size, histological 
grade, and stage [10]. Another study showed that GRP78 
expression was significantly associated with shorter 
disease-specific survival [11]. In addition, anti-vascular 
and anti-angiogenic therapies reportedly resulted in 
severe glucose and oxygen deprivation, which could lead 
to GRP78 induction in residual tumor cells and ultimately 
drug resistance [12].
GRP78 protects tumor cells from apoptosis under 
several stress conditions, including hypoxia, nutrient 
deprivation and cytotoxic chemotherapy [13–15]. 
Moreover, GRP78 expression is also a predictor of poor 
outcomes in RCC. However, the precise role of GRP78 in 
cancer following anti-angiogenic therapy remains unclear. 
We hypothesized that stress conditions induced by intrinsic 
or extrinsic stresses, such as anti-angiogenic therapy, lead to 
ER stress responses with increased GRP78 activity that aids 
tumor cell survival during oxygen and nutrient deprivation. 
In this study, we show that ER stress responses are activated 
during anti-angiogenic therapy and that inhibition of the 
UPR by GRP78 knockdown potently suppresses tumor 
progression and enhances the antitumor effects of anti-
angiogenic therapy in RCC both in vitro and in vivo. Our 
results suggest that GRP78 may serve as a novel therapeutic 
target in the current therapeutic strategy for RCC.
RESULTS
GRP78 expression is highly upregulated by 
hypoxic or hypoglycemic stress in RCC cells
To further determine whether anti-angiogenic 
therapy-induced ER stress is caused by hypoxic stress, 
hypoglycemic stress, or a combination of both, we 
examined GRP78 expression in Caki-1 cells following 
exposure to hypoxic and/or hypoglycemic conditions. 
Western blot analysis indicated that GRP78 was upregulated 
by hypoxia, hypoglycemia, and both in a time-dependent 
manner (Figure 1A–1C). These data suggest that hypoxia 
and nutrition deprivation induce ER stress in RCC cells.
Anti-angiogenic therapy induces ER stress 
response in RCC xenografts
To determine whether ER stress chaperone protein 
GRP78 is upregulated during anti-angiogenic therapy, we 
treated Caki-1 xenografts with sunitinib, a multi-tyrosine 
kinase inhibitor and potent anti-angiogenic agent, and 
used immunohistochemical staining to examine changes 
in GRP78 expression in xenografts. Sunitinib treatment 
induced intratumoral hypoxia in Caki-1 xenografts 
(Figure 2A and 2B). After five days of sunitinib treatment, 
GRP78 expression was higher than that in the control 
group (Figure 2C and 2D). GRP78 was also upregulated 
in the control group at a later stage; however, the 
treatment group still displayed higher GRP78 expression 
(Figure 2C and 2D), suggesting that ER stress response 
may be induced by oxygen or nutrient deprivation from 
anti-angiogenic therapy. However, GRP78 expression 
was not significantly altered in normal tissues following 
treatment with sunitinib (Figure S1). Comparison of tumor 
and normal tissues following anti-angiogenic therapy 
revealed that GRP78 was more highly upregulated in 
tumor tissues. These data suggest that GRP78 may serve 
as a therapeutic target of anti-angiogenic therapy in RCC.
Induction of GRP78 protects RCC cells from 
apoptosis through PERK/eIF2α signaling
To confirm the role of GRP78 in tumor cell 
survival and proliferation under stress conditions, we 
transfected Caki-1 cells with GRP78-encoded lentivirus 
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(Caki-1-GRP78) or empty vector lentivirus (Caki-1-Mock). 
Immunofluorescence imaging showed that GRP78 was 
stably expressed at a higher level in Caki-1-GRP78 cells 
than in Caki-1-Mock cells (Figure 3A). Western blot analysis 
of proteins downstream of GRP78 revealed that GRP78 
upregulation activated PERK through phosphorylation 
and increased ATF-4 (Figure 3B). We next performed a 
cell growth assay under hypoxic and/or hypoglycemic 
conditions, representing intratumoral stress conditions 
induced by anti-angiogenic therapy. Cell proliferation was 
enhanced in GRP78-overexpressing cells during hypoxia 
or hypoglycemia but these effects were removed by 
knockdown of PERK using PERK siRNA (Figure 3C). To 
further determine whether GRP78 protects tumor cells from 
apoptotic stress, apoptosis was induced by treatment with 
staurosporine, and a reduction in apoptotic cell death was 
confirmed in GRP78-overexpressing Caki-1 cells. Next, we 
knocked down PERK in GRP78-overexpressing Caki-1 cells 
using PERK siRNA plus staurosporine treatment. GRP78 
overexpression did not affect apoptotic cell death after 
knockdown of PERK in Caki-1 cells (Figure 3D), indicating 
that GRP78 exerts both pro-survival and anti-apoptotic roles 
Figure 1: Expression of GRP78 under hypoxic and glucose-deprivation conditions in RCC cells. Caki-1 cells were exposed 
to hypoxia (1% O2), low glucose, or both (hypoxia plus low glucose) for 48 h. Cell lysates were harvested at 0, 12, 24, 36, and 48 h, at 
which point, time-dependent GRP78 protein expression was analyzed under hypoxic conditions A. hypoglycemic conditions B. or both 
C. by Western blot analysis.
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under conditions of stress by activating the PERK pathway 
in RCC cells.
GRP78 knockdown suppresses tumor 
proliferation by inducing apoptosis in RCC cells
To study the inhibitory effect of GRP78 on RCC 
cell proliferation, we used GRP78 siRNA to transiently 
knock down GRP78 expression by >70% in all RCC cell 
lines (Figure 4A). GRP78 knockdown inhibited tumor 
proliferation in all RCC cell lines (Figure 4B and 4C). 
To evaluate the effect of GRP78 knockdown on the 
cell cycle, we examined cell cycle distribution by flow 
cytometry of propidium iodide-stained Caki-1 and 
UMRC-3 cells. GRP78 knockdown significantly induced 
apoptosis in Caki-1 cells (Figure 4D and S2). Western 
Figure 2: In vivo expression of GRP78 following sunitinib treatment in RCC xenografts. A–B. Caki-1 tumor xenografts 
were treated with sunitinib (40 mg/kg) or vehicle. Hypoxic areas were assessed by pimonidazole immunohistochemical staining after 
30 days of treatment. (A) Representative photographs were obtained using a light microscope (20 × magnification). (B) Hypoxic areas were 
quantitatively measured using ImageJ software. *P < 0.001 vs. vehicle. C–D, Caki-1 xenografts were treated with sunitinib for 30 days. 
GRP78 expression was then analyzed in re-treatment, 5-day treatment, and 30-day treatment tumor tissues. C. Representative photographs 
were taken using a light microscope (20 × magnification). D. Expression of immunostained GRP78 protein was quantitatively measured 
using MetaMorph 4.6 software (Universal Imaging Co., Downingtown, PA, USA). **P < 0.01 vs. vehicle, ***P < 0.01 vs. vehicle.
Oncotarget34822www.impactjournals.com/oncotarget
blot analysis showed that both caspase-3 and PARP were 
activated by GRP78 knockdown (Figure 4E and S3). To 
determine whether GRP78 knockdown enhances ER 
stress-induced apoptosis, we used MG132, a proteosome 
inhibitor that induces apoptosis via the ER stress-
mediated apoptotic pathway [16], to induce ER stress in 
Caki-1 cells. MG132 inhibited cell growth and induced 
apoptosis in Caki-1 cells and GRP78 knockdown 
enhanced MG132-induced apoptosis (Figure 4F). These 
data demonstrate that GRP78 knockdown suppresses 
cancer cell survival by inducing apoptosis in RCC cells.
GRP78 knockdown provokes apoptotic 
cell death under conditions of hypoxic and 
hypoglycemic stress by downregulating the 
PERK/ eIF2α/AFT-4 pathway
We next evaluated the effect of GRP78 knockdown 
on the survival of RCC cells under hypoxic and 
hypoglycemic conditions. Cell growth was inhibited by 
hypoxia and hypoglycemia. GRP78 siRNA successfully 
knocked down GRP78 expression induced by hypoxia and 
hypoglycemia (Figure 5A). GRP78 knockdown induced 
Figure 3: Pro-survival and anti-apoptotic roles of GRP78 overexpression though PERK/eIF2α signaling in RCC 
cells. Caki-1 cells were stably transfected with pHR-CMV-GRP78 or mock vectors. A. Representative photographs showing overexpression 
of GRP78 in Caki-1-GRP78 relative to Caki-1-Mock cells. B. Changes in the expression of GRP78 downstream effectors. Whole-cell lysates 
from Caki-1 cells transfected with pHR-CMV-GRP78 or control vectors were subjected to Western blotting to examine the expression of 
phosphorylated PERK and ATF-4. Vinculin was used as a loading control. C. Cell growth was assessed before and after knockdown of 
PERK in GRP78-overexpressing Caki-1 cells compared to parental cells. Cell growth was measured using a crystal violet assay. *P < 0.01 
vs. Mock-siScr. D. Cell cycle distribution was analyzed in GRP78-overexpressing Caki-1 cells before and after knockdown of PERK using 
FACS with PI staining. **P < 0.01 vs. Mock, ***P > 0.05.
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Figure 4: Effects of GRP78 knockdown on tumor growth and downstream effectors of ER stress pathways in RCC 
cells. A. After RNA interference using siGRP78, whole cell lysates were subjected to Western blot analysis to evaluate the effectiveness 
of GRP78 knockdown in Caki-1 cells. Vinculin was used as a loading control. B. A cell growth assay was performed following GRP78 
knockdown using various concentrations of siRNA to rule out the off-target cytotoxic effects of siRNA in Caki-1 cells, *P < 0.001. 
C. Growth of a wide panel of RCC cells following transient knockdown of GRP78. Four RCC cell lines were used for screening purposes. 
Cell growth was measured using a crystal violet assay following transient transfection with siGRP78, control siRNA, or reagent control. 
**P < 0.001 vs. scramble siRNA. D. Cell cycle analysis of Caki-1 cells treated with siGRP78. Cell cycle distribution was analyzed in Caki-1 
cells treated with siGRP78 or control siRNA using FACS with PI staining. *P < 0.001 vs. si-Scr. E. Changes in cleaved caspase (Clv. caspase) 
and cleaved PARP (Clv. PARP) were analyzed in Caki-1 cells by Western blot analysis to confirm GRP78 knockdown-induced apoptosis. 
F. Cell cycle distribution was analyzed in Caki-1 cells using FACS with PI staining, combined with MG132 treatment and siGRP78 in 
Caki-1 cells, ***P < 0.001 vs. DMSO (siGRP78).
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further growth inhibition in addition to that due to hypoxia, 
hypoglycemia, or both (Figure 5B–5D). To further study 
the effect of GRP78 inhibition combined with hypoxia or 
hypoglycemia on cell survival, we examined cell cycle 
distribution using flow cytometry. Cell cycle analysis 
showed that GRP78 knockdown significantly increased 
the number of apoptotic cells under all conditions 
examined (Figure 5E and 5F). GRP78 knockdown in cells 
suffering from hypoxic and hypoglycemic stress induced 
downregulation of phosphorylated PERK and eIF2α, 
inactivation of ATF-4, and activation of CHOP, suggesting 
that GRP78 further induces apoptotic cell death in RCC 
cells via downregulation of the PERK/eIF2α/AFT-4 
pathway under conditions of stress (Figure 5G)
In vivo knockdown of GRP78 induces tumor 
regression and enhances the anti-tumor effect 
of anti-angiogenic therapy in RCC xenografts
To confirm the effect of GRP78 inhibition on 
tumor growth in vivo, we developed Caki-1 cells stably 
expressing siGRP78 (Caki-1-shGRP78) or empty vector 
(Caki-1-Mock), which were then used to establish 
subcutaneous xenografts in mice (Figure 6A). Tumors 
were successfully developed, and consistent tumor 
growth was achieved in Caki-1-Mock xenografts. 
However, tumor growth was not successfully achieved 
in Caki-1-shGRP78 xenografts (Figure 6B, data for 
clone 2 not shown). These results suggest that GRP78 
plays a vital role in tumorigenesis and tumor progression 
in RCC. Next, to determine whether GRP78 targeting 
has a therapeutic effect in RCC and whether GRP78 
inhibition makes RCC cells more vulnerable to anti-
VEGF-targeted therapy, we developed tetracycline-
inducible shGRP78-expressing Caki-1 cells and 
established subcutaneous xenografts using these cells in 
nude mice (Figure 6C). Mice treated with doxycycline 
showed significantly reduced tumor growth compared 
with the other groups. Remarkable growth inhibition 
was observed using the combination of sunitinib and 
GRP78 suppression (Figure 6D–6F). These results 
indicate that GRP78 inhibition enhances antitumor 
activity of anti-angiogenic therapy in vivo.
DISCUSSION
VEGF-targeted anti-angiogenic therapy is a 
revolutionary treatment for the treatment of advanced 
RCC. In contrast to conventional cytotoxic therapy, anti-
angiogenic therapy suppresses tumor cells by inducing 
tumor hypoxia and nutrient deprivation. Nevertheless, 
cancer cells eventually develop compensatory mechanisms 
to survive starvation and hypoxia. One response to anti-
angiogenic therapy is the ER stress response, which allows 
tumor cells to survive hypoxia, low-nutrient conditions, 
or low-pH conditions during anti-angiogenic therapy. 
GRP78 plays a central role in this defense mechanism 
and is conservatively preserved in normal cells. However, 
a previous study showed that GRP78 heterozygosity 
impedes mammary tumor growth and inhibits tumor 
proliferation. GRP78 heterozygosity also promotes cancer 
cell apoptosis while mice exhibit normal growth, organ 
development, and antibody production, suggesting that 
GRP78 may represent a good target candidate for cancer 
therapy [7]. Here, we showed that GRP78 expression was 
induced in RCC xenografts following anti-angiogenic 
therapy, and that GRP78 knockdown effectively inhibited 
tumor proliferation and induced apoptosis in RCC both 
in vitro and in vivo by impeding UPR pathways.
The anti-tumor effects of anti-angiogenic agents 
are attributable to their ability to deprive tumors cells of 
vessels supplying oxygen and nutrients. Tumor cells can 
adapt to a low-oxygen environment, owing to hypoxia-
inducible factors (HIFs), which regulate the expression 
of more than 60 genes involved in angiogenesis, 
anaerobic glycolysis, and cell survival; the coordinated 
expression of these genes results in cellular adaptation to 
prolonged and acute hypoxia [17–19]. However, when the 
downstream effectors of HIFs are functionally blocked, 
hypoxia induces additional HIF-independent adaptive 
responses, such as ER stress, that contribute to increased 
survival under low-oxygen conditions. Thus, cells with 
a compromised ER stress pathway show significant 
sensitivity to ER stress created by the deleterious effects 
of accumulated unfolded proteins in the ER [17, 20, 21].
Since GRP78 is a master regulator of ER stress, 
UPR responses can be effectively downregulated by 
targeting GRP78. Hypoxic stress induces ER stress 
responses in a PERK- and eIF2α-dependent manner. 
UPR is orchestrated through activation of PERK, IRE1 
and ATF6, all three of which are bound and sequestered 
by GRP78 under normal conditions [22]. When an 
unfolded protein load triggers the dissociation of GRP78 
from these three sensors, UPR signaling is initiated. 
Activated PERK rapidly increases phosphorylation of 
the translation initiation factor eIF2α, which prevents the 
influx of additional nascent polypeptides to the ER [22] 
and upregulates genes that promote amino acid sufficiency 
and redox homeostasis [23–25]. Phosphorylation of 
eIF2α plays a central role in coupling the rate of protein 
synthesis to the cellular response to different types of 
stress and energy availability. A rapid and robust increase 
in eIF2α phosphorylation at Ser51 is observed in response 
to hypoxia [26]. This modification correlates with a 
reduction in protein synthesis rate and is not observed 
following other stresses, such as low serum or genotoxic 
stress. Phosphorylation of eIF2α is independent of HIF1α 
status, as it also occurs in a similar manner in HIF1α−/− 
mouse embryonic fibroblasts [9, 27]. In the present study, 
inhibition of GRP78 reduced the PERK phosphorylation 
in RCC cells. In addition, GRP78 knockdown inhibited the 
activation of both PERK and eIF2α under both normoxic 
and hypoxic conditions, suggesting that GRP78 may be 
the best target for inhibiting the ER stress response.
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Figure 5: Changes in cell survival and apoptosis during hypoxia and hypoglycemia by GRP78 knockdown in RCC 
cells. A. Whole cell lysates following transient knockdown of GRP78 using siGRP78 were subjected to Western blot analysis to confirm 
suppression of upregulated GRP78 during hypoxic and hypoglycemic conditions. Vinculin was used as a loading control. B and C. Cell 
growth was evaluated in Caki-1 cells using a crystal violet assay following GRP78 knockdown during hypoxic and/or hypoglycemic 
conditions. *P < 0.001 vs. si-Scr, **P < 0.001 vs. siScr in normoxia+glucose, ***P < 0.0001 vs. siScr in normoxia+glucose. (C) Relative 
growth suppression was calculated by internal comparison. D. Representative photos of cell growth were taken, 20X magnification. 
E and F. Cell cycle distribution was analyzed in Caki-1 cells treated with siGRP78 or control siRNA during hypoxic and hypoglycemic 
conditions using FACS with PI staining. *P < 0.001 vs. siScr. G. Western blot of proteins extracted from Caki-1 cells treated with either 
siGRP78 or scrambled siRNA following exposure to hypoxic and hypoglycemic stress. Vinculin was used as a loading control.
Oncotarget34826www.impactjournals.com/oncotarget
Figure 6: In vivo effects of GRP78 knockdown with sunitinib treatment on tumor growth in RCC xenografts. A. Cell 
lysates were harvested from Caki-1 cells stably expressing shGRP78 or control vector and subjected to Western blot analysis to assess 
knockdown efficiency. Vinculin was used as a loading control. B. Tumor growth of xenografts from Caki-1 cells stably expressing shGRP78 
or control vector were evaluated by measuring tumor size each week (n = 12 mice per group). *P < 0.001 vs. shControl. C. Cell lysates 
were harvested from Caki-1 cells stably expressing tetracycline-inducible shGRP78 or control vector and subjected to Western blot analysis 
to assess knockdown efficiency induced by doxycycline. Vinculin was used as a loading control. D–F. Xenografts were developed in nude 
mice using Caki-1 cells stably expressing tetracycline-inducible shGRP78 or control vector. Tumor size was measured every three days 
following treatment with doxycycline or vehicle combined with sunitinib or vehicle (n = 6 mice per group). (E) Representative photos of 
tumor xenografts were taken before sacrifice. (F) Relative tumor suppression in each treatment group compared to control. **P < 0.001 vs. 
vehicle, ***P < 0.001.
Oncotarget34827www.impactjournals.com/oncotarget
CHOP is downstream of the PERK and eIF-2α 
phosphorylation cascade. Activation of PERK and eIF2a 
induces CHOP accumulation, which plays a critical role 
in the switch from pro-adaptive to pro-apoptotic signaling 
[9]. CHOP promotes protein synthesis and oxidation in 
the stressed ER, thereby contributing to the induction of 
cell death. It also modulates the Bcl-2 family of proteins 
and growth and arrest DNA damage inducible protein 
34 (GADD34), causing damage to the mitochondrial 
membrane and the release of cytochrome c into the cytosol 
[28–30]. Our results show that the pro-apoptotic effects of 
GRP78 inhibition occur via CHOP activation, subsequent 
to PERK and eIF2α activation in RCC cells.
Inhibition of GRP78 halts the important defense 
mechanism required for survival in starving tumor cells 
and makes tumor cells more vulnerable to environmental 
stresses such as hypoxia and glucose deprivation. 
Combination therapy that stimulates ER stress-mediated 
apoptotic pathways while simultaneously downregulating 
the induction of pro-survival GRP78 may substantially 
enhance drug efficacy. For this reason, targeting ER 
stress responses through GRP78 inhibition may be a 
reasonable approach for combination cancer therapy 
with VEGF-targeted anti-angiogenic agents. In addition 
to the protective role of GRP78 in cancer cells, GRP78 
also promotes tumor proliferation. In the present study, 
overexpression of GRP78 increased the proliferation 
of RCC cells, and GRP78 knockdown had significant 
antitumor effects under normal conditions without 
stresses (i.e., hypoxia and glucose deprivation). These 
results demonstrate that GRP78 plays a critical role 
in tumor proliferation and progression even in normal 
tumor environments, suggesting that GRP78 targeting 
may represent an effective cancer treatment option as 
monotherapy.
In conclusion, our study showed that the inhibition 
of GRP78 successfully enhanced the antitumor effect of 
sunitinib in RCC, indicating that GRP78 is an excellent 
target for combination therapy with anti-angiogenic 
treatments. Targeting ER stress responses may serve as 
a novel approach to enhance the therapeutic efficacy of 
anti-angiogenic agents and to delay the development of 
resistance.
MATERIALS AND METHODS
Cell culture and reagents
Two human RCC cell lines, Caki-1 and Caki-2, 
were obtained from the American Type Culture Collection 
(ATCC) and maintained in McCoy’s 5A Medium 
(HyClone, Thermo Fisher Scientific) supplemented with 
10% fetal bovine serum (FBS). Two additional human 
RCC cell lines, UMRC-3 and UMRC-6, were kindly 
provided by Dr. P. Black (Vancouver Prostate Centre, 
University of British Columbia, Vancouver, Canada) 
and maintained in Minimal Essential Medium (MEM; 
Invitrogen) supplemented with 10% FBS and 2 mmol/L 
L-glutamine. All cells were cultured at 37°C in a 
humidified atmosphere with 5% CO2. For all studies, cell 
lines were passaged for a maximum of two months.
Transient transfections
To develop cells with transient GRP78 knockdown, 
Caki-1 and UMRC-3 cells were transiently transfected 
with a 19-bp small interfering RNA (siRNA) targeting 
GRP78 (sense: 5′-GGAGCGCAUUGAUACUAGA-3′, 
anti-sense: 5′-GCCUAGGUCUCUUAGAUGA-3′) or a 
non-silencing siRNA (si-Scr) [31]. Caki-1 and UMRC-
3 cells were seeded onto 6-well plates at a density of 
1.2 × 105 cells/well. At 30%–50% confluence, cells were 
transfected for 16 h with the siRNAs using Lipofectamine 
2000 (Invitrogen Life Technologies) diluted with 
OPTIMEM (Invitrogen Life Technologies) according 
to the manufacturer’s instructions. After transfection, 
the medium was replaced with fresh medium, and cells 
were incubated for 48–72 h according to the purpose 
of the experiment. To develop cells with transient 
protein kinase-like ER kinase (PERK) knockdown, 
GRP78-overexpressing Caki-1 and parental Caki-1 
cells were transfected with PERK siRNA (Santa Cruz 
Biotechnology).
Cloning and stable transfections
The pHR-CMV lentivirus system was used as 
described previously to generate GRP78-overexpressing 
Caki-1 cells [31]. Briefly, human GRP78 cDNA was 
subcloned into the pHR-CMV lentiviral vector. HEK293T 
cells were then transiently transfected with GRP78-pHR-
CMV, along with packaging vectors, VSVG and R8.91. 
Forty-eight hours after transfection, lentivirus-containing 
culture medium was collected and added to Caki cells. 
The pLKO.1 lentivirus system was used to develop Caki-
1 GRP78 knockdown cells stably expressing shGRP78. 
Oligonucleotides for GRP78 small hairpin RNA (shRNA) 
were synthesized and cloned into pLKO.1 by Sigma 
Chemical Company. shGRP78-overexpressing Caki-1 
clones were then selected with puromycin (Invitrogen). 
The pSingle-tTS-shRNA vector system (Clontech) was 
used to generate stable tetracycline-inducible knockdown 
of GRP78 in Caki-1 cells. GRP78-specific (sense: 
5′-TCGAGGGGAGCGCATTGATACTAGATTCAAG 
AGATCTAGTATCAATGCGCTCCTTTTTTACGCG 
TA-3′, antisense: 
5′-AGCTTACGCGTAAAAAAGGAGCGCATTGAT 
ACTAGATCTCTTGAATCTAGTATCAATGCGC 
TCCCC-3′) and control non-targeting 
shRNA sequences (sense: 5′-TCGAGG 
AGTTCAACGAGTATCAGCATTCAAGAGATG 
CTGATACTCGTTGAACTTTTTTTACGCGTA-3′, 
antisense: 
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5′-AGCTTACGCGTAAAAAAAGTTCAACGAG 
TATCAGCATCTCTTGAATGCTGATACTCGTT 
GAACTCC-3′) were designed following the 
manufacturer’s protocol. Annealed, double-stranded 
shRNA oligonucleotides were cloned into the XhoI/HindIII 
site of the pSingle-tTS-shRNA vector. Cloning was 
confirmed by nucleotide sequencing. The pSingle-tTS 
GRP78 shRNA or pSingle-tTS non-silencing control 
shRNA was transfected into Caki-1 cells using Xtreme 
Gene 9 (Roche) diluted with OPTIMEM according to 
the manufacturer’s instructions. Transfected cells were 
selected using 400 μg/mL G418 (Roche) and maintained 
in medium containing 200 μg/mL G418. Stable cell clones 
were then confirmed for doxycycline-induced GRP78 
gene silencing by both Western blot analysis and reverse 
transcription-polymerase chain reaction (RT-PCR). After 
polyclonal selection and confirmation, stable cell lines 
were frozen at early (less than 10) passages.
Development of hypoxia and glucose-deprivation
Hypoxic conditions (1% oxygen) were induced 
using a hypoxia chamber (Coy Corporation). Cells were 
exposed to hypoxia (1% oxygen) and maintained in the 
hypoxia chamber during the assay. Deprivation of glucose 
was achieved by using glucose-free media supplemented 
with low glucose (2 mmol/L).
Cell viability assay
Cells were seeded onto six-well plates at 
1.2 × 105 cells per well, incubated overnight, and 
transfected. After incubation for an additional 72 h, cells 
were fixed with 1% glutaraldehyde and stained with a 
0.5% crystal violet solution. Cells were then washed with 
water, and any remaining crystal violet was resolved with 
Sorensen’s solution. Absorbance was measured at 562 nm 
on a spectrophotometer. All experiments were performed 
in triplicate.
Cell cycle analysis and apoptosis
Cells were harvested and fixed with 70% alcohol 
as a single-cell suspension. Fixed cells were collected by 
centrifugation and washed with phosphate-buffered saline 
(PBS). Cells were incubated with RNase A (1 mg/mL) for 
30 min at 37°C and then incubated with propidium iodide 
(PI; 20 μg/mL; Sigma Chemical) for 30 min. Relative 
DNA content was determined using a FACSCanto II flow 
cytometer and FACSDiva software (BD Bioscience).
Western blot analysis
Cellular proteins were harvested in RIPA lysis 
buffer containing vanadate, phosphatase inhibitor and 
phenylmethanesulfonyl fluoride. Proteins were resolved 
by electrophoresis in polyacrylamide gels and transferred 
to a nitrocellulose membrane using a Trans-Blot system 
(Bio-Rad) as described previously [14]. Membranes were 
blocked in 5% skim milk diluted with Tris-buffered saline 
and Tween 20 (TBST) for 1 h at room temperature and 
incubated with primary antibodies diluted in 3% skim 
milk in TBST for 1 h at room temperature or overnight 
at 4°C. Antibodies against the following proteins were 
used for Western blot analysis (all from Santa Cruz 
Biotechnology): GRP78 (C–20) (diluted 1:1000), PERK 
(1:1000), p-PERK (1:250–500), p-eIF2α (1:250–500), 
GADD153 (1:500), CREB-2 (1:500), and vinculin 
(1:5000). Anti-goat, anti-rabbit, and anti-mouse IgG 
secondary antibodies (1:5000) were used. Amersham 
enhanced chemiluminescence reagents (GE Healthcare) 
or Supersignal chemiluminescence reagents (Thermo 
Scientific) were used to detect immunoreactive proteins.
Immunofluorescence
Cells were seeded onto glass coverslips in six-well 
plates and allowed to attach overnight. To evaluate 
baseline expression of GRP78 in wild-type RCC cells 
and GRP78-overexpressing cells, cells were washed 
with ice-cold PBS, fixed with ice-cold methanol mixed 
with acetone (3:1) for 10 min at room temperature, and 
treated with 0.25% Triton X-100 in PBS for 10 min. After 
blocking with 3% bovine serum albumin for 30 min, cells 
were then incubated with anti-GRP78 (C–20) antibody at 
room temperature for 1 h, washed three times with TBS, 
and incubated with Alexa Fluor 488-conjugated anti-goat 
antibody for 1 h in a dark room. Nuclei were stained with 
DAPI. Immunofluorescence was imaged using a Zeiss 
confocal laser scanning microscope.
In vivo xenograft models
All animal experiments were conducted in 
compliance with accepted standards of the University of 
British Columbia Committee on Animal Care. General 
anesthesia of mice was induced and maintained by inhaled 
isoflurane. Six- to eight-week-old female nu/nu nude 
mice were subcutaneously injected in the flank area with 
a cell suspension containing 3 × 106 tumor cells. Caki-1 
cells were used to evaluate GRP78 expression following 
sunitinib treatment. Caki-1 cells stably expressing 
doxycycline-inducible shGRP78 were used to investigate 
the effect of GRP78 knockdown in vivo. When the tumor 
size reached 150–250 mm3, mice were randomized to 
receive vehicle, sunitinib, doxycycline, or sunitinib and 
doxycycline for 30 days (n = 8 mice per group). Every 
three days, tumor size was measured using calipers and 
body weight was determined. Tumor volume was calculated 
as length × width × height × 0.5. After treatment was 
complete, mice were euthanized in a CO2 chamber followed 
by cervical dislocation. Tumors were fixed in 10% formalin 
for immunohistochemical staining or frozen at − 80°C for 
protein and RNA analyses.
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Immunohistochemistry
Formalin-fixed, paraffin-embedded tumors were 
cut into 4-μm sections, which were deparaffinized, 
rehydrated with xylene and ethanol, and transferred 
into 0.02% Triton for permeabilization. Slides in citrate 
buffer (pH 6) were heated in a steamer for 3 min, 
washed in PBS for 5 min, incubated in 3% bovine 
serum albumin, transferred into 3% H2O2, and incubated 
with anti-GRP78 antibody overnight. For quantitative 
analysis of immunohistochemical staining, expression 
of pimonidazole was measured using ImageJ and 
expression of GRP78 was measured using MetaMorph 
4.6 software (Universal Imaging Co., Downingtown, 
PA, USA). Automated counting of numbers of pixels 
in the four different intensity zones were received and 
after determining these numbers, we applied them to a 
simple algebraic formula as shown below to determine 
the score of the image. Score = (Number of pixels in a 
zone) × (Score of the zone) / (Total number of pixels in 
the image).
Statistical analysis
All experiments were performed at least three times. 
Results are presented as the means ± standard error (SE). 
Statistical analysis was performed using SigmaPlot 12 
(Systat Software Inc., Chicago, IL, USA). Student’s t-test 
was applied for two-group comparison. P values less than 
0.05 were considered to indicate statistical significance.
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